Evidence Explorer · MS-N258 · Mind–body and psychological support · stress management versus recurrence and survival · Appraised November 6, 2026
An 11-year follow-up of a randomized stress-management trial reported fewer deaths and favorable disease-free survival signals after a 10-week cognitive-behavioral program, but the small number of events, wide confidence intervals and secondary nature of the analysis make cancer-control benefit uncertain.
Evidence at a glance
- Benefit signal: Psychological support has established stress benefits; this follow-up reported a survival signal that remains unconfirmed as a treatment effect.
- Certainty: Low for cancer-control outcomes despite randomization; the long-term analysis was event-limited and not a replicated primary efficacy trial.
- Risk context: The main risk is interpretive—blaming patients or substituting stress management for oncologic therapy.
- Cancer-control relevance: Direct cancer-control question: intriguing but insufficient evidence to claim reduced recurrence or improved survival.
What was studied
The parent trial randomized 240 women with stage 0–IIIb breast cancer after surgery to a 10-week group cognitive-behavioral stress-management program (120) or a one-day psychoeducational seminar (120).
The later analysis examined recurrence and mortality after a median of about 11 years. These were long-term clinical outcomes rather than the original short-term stress endpoints.
What the study found
The reported all-cause mortality hazard ratio was 0.21 (95% CI 0.05 to 0.93; p=.04). In the invasive-cancer subgroup, breast-cancer mortality and disease-free interval also favored the intervention (reported p=.006 and p=.011).
A 2026 updated meta-analysis of 24 psychosocial-intervention RCTs and 4,795 participants reported a small pooled overall-survival association (summary HR 0.87, 95% CI 0.77 to 0.99; I²=45%), but interventions and populations varied and some hazard ratios were derived from survival curves.
What this does not establish
The very wide mortality confidence interval signals few events and substantial imprecision. Long-term subgroup and secondary analyses are vulnerable to chance, treatment-era differences and post-randomization influences.
The pooled meta-analysis does not show that stress causes cancer progression, identify a specific effective psychotherapy or justify replacing anticancer treatment. An individual patient-data analysis and prospective replication would be needed for stronger causal confidence.
Safety and practical context
Stress-management programs may help coping regardless of cancer-control uncertainty. They should never be framed as a test of positivity, willpower or responsibility for recurrence.
Severe depression, suicidality, trauma symptoms or uncontrolled physical symptoms need appropriate clinical care.
Questions for the care team
- Is the program being offered for coping and quality of life, with survival uncertainty stated clearly?
- Will anyone use this evidence to imply that stress or attitude caused the cancer?
- Are standard surveillance and anticancer treatments continuing unchanged?
Sources and identifiers
Funding and conflicts: The long-term report and meta-analysis have separate funding and disclosure statements; complete details were not fully verified from the accessible abstracts.
Source access and dates: Primary trial follow-up and meta-analysis abstracts were appraised; complete historical full text was not independently verified. Sources checked November 6, 2026. Last literature search November 6, 2026.
Educational evidence summary, not individualized medical advice. Psychological and sleep interventions should complement—not replace—oncology, palliative, mental-health or sleep-medicine care.
